Oncology Biomarkers: Global Markets

Oncology Biomarkers: Global Markets

Report Scope:

This study provides a comprehensive analysis of oncology biomarkers on a global basis. It aims to offer a range of information, from detailed market analyses within cancer types to overall industry trends, to quantify and qualify the market for products and services in the oncology biomarkers segment. Current and projected market forecasts during the forecast period (2023 to 2028) are discussed. Figures for 2023 are estimated, except where actual results have been reported.

This report includes forecasts by biomarker type, cancer type, application, and region from 2023 through 2028. The report also includes an analysis of leading and emerging competitors in the current worldwide oncology biomarkers market. The competitive environment is examined with a particular focus on how new products and technologies influence the current standard of care.

Report Includes:

21 data tables and 60 additional tables

An in-depth analysis of the global oncology biomarkers market

Analyses of global market trends, with data from 2020, 2021, 2022, and projections of compound annual growth rates (CAGRs) through 2028

Characterization and quantification of biomarkers market by type, profiling technology, application, cancer type, and region

Discussion on market drivers, challenges and key market strategies and trends

Information on emerging products and technologies, new analytical platforms, novel immunoassays, and bioinformatics tools and discussion on the use of biomarkers in cancer drug development

Profiles of the competitive landscape with an overview of competitor growth strategies and opportunities

Company profiles of major players within the industry, including Abbott, F. Hoffmann-La Roche Ltd., Merck KGaA, Siemens Healthineers AG, and Thermo Fisher Scientific Inc.